A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Completed · Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

The primary objective of the study was to compare the safety and efficacy of multiple doses of upadacitinib versus placebo in adults with moderately to severely active rheumatoid arthritis (RA) on stable background methotrexate therapy who had not shown an adequate response to methotrexate alone.

Key facts

Study ID

NCT02066389

Run by

AbbVie

People needed

300

Starts

2014-03-26

Expected to finish

2015-07-02

Last updated by the study team

2021-07-30

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with RA based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 ACR/European League against Rheumatism (EULAR) criteria for ≥ 3 months.
• Have active RA as defined by the following minimum disease activity criteria:
• ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline Visits.
• ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
• high-sensitivity C-reactive protein (hsCRP) > upper limit of normal (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (CCP) at Screening.
• Subjects must have been receiving oral or parenteral methotrexate therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to Baseline Visit. Subjects should also be on a stable dose of folic acid (or equivalent) for at least 4 weeks prior to Baseline Visit. Subjects should continue with their stable doses of methotrexate and folic acid throughout the study.
• Except for MTX, subjects must have discontinued all oral disease-modifying anti-rheumatic drugs (DMARDs) prior to Baseline Visit as specified below or for at least five times the mean terminal elimination half-life of a drug, whichever is longer:
• ≥ 4 weeks prior to Baseline Visit for minocycline, penicillamine, sulfasalazine, hydroxychloroquine, chloroquine, azathioprine, gold formulations, cyclophosphamide
• ≥ 8 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to a washout procedure (i.e., 11 days washout with colestyramine, or 30 days washout with activated charcoal)
• Subject has a negative tuberculosis (TB) Screening Assessment. If the subject has evidence of a latent TB infection, the subject must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is longer) of an ongoing TB prophylaxis or have documented completion of a full course of TB prophylaxis, prior to Baseline Visit.
• Subjects can be taking non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen, oral corticosteroids (equivalent to prednisone ≤ 10 mg), or inhaled corticosteroids at a stable dose for at least 4 weeks prior to Baseline Visit for stable medical conditions and should be kept at a stable dose throughout the study. NSAIDs, acetaminophen, tramadol, codeine, hydrocodone and propoxyphene taken as needed are allowed but may not be taken 24 hours prior to any study visit. Oral and inhaled corticosteroids taken as needed are allowed but may not be taken 24 hours prior to any study visit.
• Subjects must have discontinued high potency opiates including (but not limited to): oxycodone, oxymorphone, fentanyl, levorphanol, buprenorphine, methadone, hydromorphone, and morphine at least 4 weeks prior to Baseline Visit.

You may not qualify if…

• Female who is pregnant or breastfeeding.
• Prior exposure to Janus activated kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib).
• Prior exposure to any investigational or approved biologic RA therapy.
• Receipt of any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives of the drug (whichever is longer) prior to Week 0 Visit.
• Current or expected need of other immunosuppressant medications, except methotrexate. Use of oral intake of > 10 mg prednisone/day or equivalent corticosteroid therapy (see inclusion criterion 7).
• Subject has been treated with intra-articular or parenteral administration of corticosteroids in the preceding 8 weeks prior to the Week 0 Visit.
• Screening laboratory values meeting the following criteria:
• Serum aspartate transaminase (AST) or alanine transaminase (ALT) > 1.5 × ULN
• Estimated glomerular filtration rate (eGRF) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula < 40 mL/min/1.73 m²
• Total white blood cell count (WBC) < 3,000/µL
• Absolute neutrophil count (ANC) < 1,200/µL
• Platelet count < 100,000/µL
• Absolute lymphocytes count < 750/ µL
• Hemoglobin < 9 gm/dL

Where it is running

• Omega Research Consultants, LLC /ID# 125780 — DeBary, Florida, United States
• Lovelace Scientific Resources /ID# 127324 — Venice, Florida, United States
• North Georgia Rheumatology Grp /ID# 125779 — Lawrenceville, Georgia, United States
• PRN Professional Research Network of Kansas, LLC /ID# 126148 — Wichita, Kansas, United States
• The Center for Rheumatology & /ID# 127323 — Wheaton, Maryland, United States
• Summit Medical Group /ID# 125776 — Clifton, New Jersey, United States
• Arthritis and Osteo Assoc /ID# 134994 — Las Cruces, New Mexico, United States
• Altoona Ctr Clinical Res /ID# 125777 — Duncansville, Pennsylvania, United States
• Emkey Arthritis and Osteo Clin /ID# 134716 — Wyomissing, Pennsylvania, United States
• Accurate Clinical Research /ID# 126535 — Houston, Texas, United States
• Mountain State Clinical Resear /ID# 127089 — Clarksburg, West Virginia, United States
• MHAT Trimontsium /ID# 127311 — Plovdiv, Bulgaria
• UMHAT Pulmed OOD /ID# 127307 — Plovdiv, Bulgaria
• MHAT Kaspela /ID# 127315 — Plovdiv, Bulgaria
• Diagnostic Consultative Center /ID# 127313 — Sofia, Bulgaria
• UMHAT Sv. Ivan Rilski /ID# 127314 — Sofia, Bulgaria
• UMHAT Sv. Ivan Rilski /ID# 131608 — Sofia, Bulgaria
• Diagnostic Consultative Center /ID# 127312 — Varna, Bulgaria
• Corp de Beneficencia Osorno /ID# 127337 — Osorno, Chile
• Quantum Research LTDA. /ID# 127338 — Puerto Varas, Chile
• Revmatologicky ustav Praha /ID# 127317 — Prague, Praha 2, Czechia
• Nuselská poliklinika, Revmatologie /ID# 127318 — Prague, Praha 4, Czechia
• Revmatologie Bruntal, s.r.o /ID# 126881 — Bruntál, Czechia
• Artroscan s.r.o. /ID# 126845 — Ostrava, Czechia
• C.V. Mehta MD, Med Corporation /ID# 126380 — Hemet, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.